Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer.

Autor:	Murakami T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Obata H; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Akitake N; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan shiota@uro.med.kyushu-u.ac.jp., Takeuchi A; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Kashiwagi E; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Inokuchi J; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Tatsugami K; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Eto M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2018 Jul; Vol. 38 (7), pp. 4115-4121.
DOI:	10.21873/anticanres.12702
Abstrakt:	Background/aim: We aimed to identify prognostic and predictive factors for anti-androgen withdrawal syndrome (AWS) to help guide decisions on anti-androgen withdrawal in castration-resistant prostate cancer (CRPC). Patients and Methods: This study included 95 patients with prostate cancer which progressed to CRPC despite primary androgen-deprivation therapy (ADT). AWS was defined as >50% prostate-specific antigen decline after anti-androgen withdrawal. Associations between AWS, and clinicopathological factors and prognosis were investigated. Results: Among the 95 patients, 84 (88.4%) underwent anti-androgen withdrawal, among whom AWS was recognized in nine (10.8%). Gleason score and response duration to primary ADT were predictors of AWS. Long duration of response to primary ADT was also associated with better progression-free survival [hazard ratio (HR)=0.021, 95% confidence interval (CI)=0.0025-0.14, p<0.0001] and overall survival (HR=0.0042, 95% CI=0.0001-0.089, p<0.0001). Age (HR=7.19, 95% CI=1.08-54.27, p=0.041) and radiological/clinical progression (HR=3.14, 95% CI=1.35-6.43, p=0.010) were associated with worse overall survival. Intriguingly, radiological/clinical progression was associated with the differential effect of anti-androgen withdrawal on overall survival (interaction p=0.031). Conclusion: Patients who suffer radiological/clinical progression are unsuitable candidates for anti-androgen withdrawal. (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu